Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Knox JJ"" wg kryterium: Autor


Tytuł:
Progression-free survival as endpoint in metastatic RCC?
Autorzy:
Knox JJ (AUTHOR)
Pokaż więcej
Źródło:
Lancet. 8/9/2008, Vol. 372 Issue 9637, p427-429. 3p.
Czasopismo naukowe
Tytuł:
A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada.
Autorzy:
Ramjeesingh R; Division of Medical Oncology, Department of Medicine, Nova Scotia Health, Dalhousie University, Halifax, NS B3H 2Y9, Canada.
Chaudhury P; Department of Surgery and Oncology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC H4A 3J1, Canada.
Tam VC; Division of Medical Oncology, Department of Oncology, University of Calgary, Calgary, AB T2N 4N2, Canada.
Roberge D; Department of Radiology, Radiation Oncology and Nuclear Medicine, University of Montreal, Montreal, QC H3T 1A4, Canada.
Lim HJ; Division of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada.
Knox JJ; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Asselah J; Department of Medicine, Division of Medical Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Doucette S; IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada.
Chhiber N; IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada.
Goodwin R; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Jul 25; Vol. 30 (8), pp. 7132-7150. Date of Electronic Publication: 2023 Jul 25.
Typ publikacji:
Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
MeSH Terms:
Biliary Tract Neoplasms*/drug therapy
Cisplatin*/therapeutic use
Gemcitabine*/therapeutic use
Humans ; Canada ; Capecitabine/therapeutic use
Czasopismo naukowe
Tytuł:
Egg-laying and locomotory screens with C. elegans yield a nematode-selective small molecule stimulator of neurotransmitter release.
Autorzy:
Harrington S; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.
Knox JJ; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
Burns AR; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
Choo KL; The Department of Chemistry, University of Toronto, Toronto, Canada.
Au A; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada.
Kitner M; USDA-ARS Horticultural Crops Research Laboratory, Corvallis, OR, USA.
Haeberli C; Department of Medical Parasitology and Infection Biology, Swiss-Tropical and Public Health Institute, (Swiss TPH), Basel, Switzerland.; Faculty of Science, University of Basel, Basel, Switzerland.
Pyche J; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.
D'Amata C; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.
Kim YH; The Department of Chemistry, University of Toronto, Toronto, Canada.
Volpatti JR; Program in Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Canada.; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada.
Guiliani M; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada.
Snider J; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.
Wong V; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.
Palmeira BM; Department of Comparative Biology and Experimental Medicine, Host-Parasite Interactions (HPI) Program, Faculty of Veterinary Medicine, University of Calgary, Calgary, Canada.
Redman EM; Department of Comparative Biology and Experimental Medicine, Host-Parasite Interactions (HPI) Program, Faculty of Veterinary Medicine, University of Calgary, Calgary, Canada.
Vaidya AS; Institute for Integrative Genome Biology, University of California, Riverside, CA, USA.; Department of Botany and Plant Sciences, University of California, Riverside, CA, USA.
Gilleard JS; Department of Comparative Biology and Experimental Medicine, Host-Parasite Interactions (HPI) Program, Faculty of Veterinary Medicine, University of Calgary, Calgary, Canada.
Stagljar I; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, Canada.; Department of Biochemistry, University of Toronto, Toronto, Canada.; Mediterranean Institute for Life Sciences, Split, Croatia.; School of Medicine, University of Split, Split, Croatia.
Cutler SR; Institute for Integrative Genome Biology, University of California, Riverside, CA, USA.; Department of Botany and Plant Sciences, University of California, Riverside, CA, USA.
Kulke D; Research Parasiticides, Bayer Animal Health GmbH, Monheim, Germany.; Department of Biomedical Sciences, Iowa State University, Ames, IA, USA.; Global Innovation, Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
Dowling JJ; Program in Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Canada.; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada.
Yip CM; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada.; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada.
Keiser J; Department of Medical Parasitology and Infection Biology, Swiss-Tropical and Public Health Institute, (Swiss TPH), Basel, Switzerland.; Faculty of Science, University of Basel, Basel, Switzerland.
Zasada I; USDA-ARS Horticultural Crops Research Laboratory, Corvallis, OR, USA.
Lautens M; The Department of Chemistry, University of Toronto, Toronto, Canada.
Roy PJ; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada. .; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada. .; Department of Molecular Genetics, University of Toronto, Toronto, Canada. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2022 Aug 24; Vol. 5 (1), pp. 865. Date of Electronic Publication: 2022 Aug 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Caenorhabditis elegans*
Nematoda*
Acetylcholinesterase ; Animals ; Antinematodal Agents/pharmacology ; Humans ; Neurotransmitter Agents ; Phylogeny
Czasopismo naukowe
Tytuł:
The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer.
Autorzy:
Duan K; Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada. .; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. .
Jang GH; Ontario Institute for Cancer Research, Toronto, ON, Canada.
Grant RC; Ontario Institute for Cancer Research, Toronto, ON, Canada.; Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Wilson JM; Ontario Institute for Cancer Research, Toronto, ON, Canada.
Notta F; Ontario Institute for Cancer Research, Toronto, ON, Canada.; Division of Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
O'Kane GM; Ontario Institute for Cancer Research, Toronto, ON, Canada.; Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Knox JJ; Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Gallinger S; Ontario Institute for Cancer Research, Toronto, ON, Canada.; Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.; Hepatobiliary/Pancreatic Surgical Oncology Program, University Health Network, Toronto, ON, Canada.
Fischer S; Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada. .; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. .; Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Jul 22; Vol. 11 (1), pp. 14951. Date of Electronic Publication: 2021 Jul 22.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Down-Regulation*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*metabolism
Carcinoma, Pancreatic Ductal/*drug therapy
GATA6 Transcription Factor/*metabolism
Pancreatic Neoplasms/*drug therapy
Adult ; Aged ; Biomarkers, Tumor/genetics ; Carcinoma, Pancreatic Ductal/genetics ; Carcinoma, Pancreatic Ductal/metabolism ; Diagnosis, Computer-Assisted ; Female ; GATA6 Transcription Factor/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Middle Aged ; Observer Variation ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/metabolism ; Prognosis ; Prospective Studies ; Survival Analysis ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
Autorzy:
Pham NA; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Radulovich N; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Ibrahimov E; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Martins-Filho SN; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Li Q; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Pintilie M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Weiss J; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Raghavan V; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Cabanero M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Denroche RE; Ontario Institute of Cancer Research (OICR), Toronto, ON, Canada.
Wilson JM; Ontario Institute of Cancer Research (OICR), Toronto, ON, Canada.
Metran-Nascente C; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Borgida A; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Hutchinson S; Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Dodd A; Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Begora M; Department of Pathology, UHN Program in BioSpecimen Sciences, University Health Network, Toronto, ON, Canada.
Chadwick D; Department of Pathology, UHN Program in BioSpecimen Sciences, University Health Network, Toronto, ON, Canada.
Serra S; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Knox JJ; Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Gallinger S; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Division of General Surgery, University of Toronto, Toronto, ON, Canada.
Hedley DW; Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Muthuswamy L; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Tsao MS; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 May 19; Vol. 11 (1), pp. 10619. Date of Electronic Publication: 2021 May 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Xenograft Model Antitumor Assays*
Biliary Tract Neoplasms/*pathology
Duodenal Neoplasms/*pathology
Organoids/*pathology
Pancreatic Neoplasms/*pathology
Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Biliary Tract Neoplasms/drug therapy ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Duodenal Neoplasms/drug therapy ; Humans ; Mice, Inbred NOD ; Mice, SCID ; Mutation/genetics ; Organoids/drug effects ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Autorzy:
Fung AS; Tom Baker Cancer Centre, Calgary, AB, Canada.; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Tam VC; Tom Baker Cancer Centre, Calgary, AB, Canada.; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Meyers DE; Tom Baker Cancer Centre, Calgary, AB, Canada.; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Sim HW; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
Knox JJ; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Zaborska V; BC Cancer Agency, Vancouver Centre, Vancouver, BC, Canada.; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Davies J; BC Cancer Agency, Vancouver Centre, Vancouver, BC, Canada.
Ko YJ; Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, ON, Canada.
Batuyong E; Tom Baker Cancer Centre, Calgary, AB, Canada.
Samawi H; St. Michael's Hospital, Toronto, ON, Canada.
Cheung WY; Tom Baker Cancer Centre, Calgary, AB, Canada.; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Lee-Ying R; Tom Baker Cancer Centre, Calgary, AB, Canada.; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2020 Jul; Vol. 9 (13), pp. 4640-4647. Date of Electronic Publication: 2020 May 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anilides/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Phenylurea Compounds/*therapeutic use
Pyridines/*therapeutic use
Sorafenib/*therapeutic use
Canada ; Carcinoma, Hepatocellular/mortality ; Clinical Trials, Phase III as Topic ; Databases, Factual ; Female ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/mortality ; Male ; Middle Aged ; Patient Selection ; Randomized Controlled Trials as Topic ; Time Factors ; Ramucirumab
Czasopismo naukowe
Tytuł:
Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.
Autorzy:
Alghamdi MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.; College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Amaro CP; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Lee-Ying R; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Sim HW; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Samwi H; St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Chan KK; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.; Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada.
Knox JJ; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Ko YJ; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
Swiha M; University of Western Ontario, London, ON, Canada.; Menoufia University, Shebin El Kom, Egypt.
Batuyong E; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Romagnino A; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
Cheung WY; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Tam VC; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Pokaż więcej
Corporate Authors:
Hepatocellular Carcinoma - Cancer Health Outcomes Research Database (HCC - CHORD) Consortium
Źródło:
Cancer medicine [Cancer Med] 2020 Jul; Vol. 9 (14), pp. 4918-4928. Date of Electronic Publication: 2020 Jun 11.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Sorafenib/*therapeutic use
Antineoplastic Agents/pharmacology ; Canada ; Carcinoma, Hepatocellular/pathology ; Female ; Humans ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Sorafenib/pharmacology ; Treatment Outcome
Czasopismo naukowe
Tytuł:
A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome.
Autorzy:
Amin S; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Rattner J; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
Keramati MR; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.; Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.
Farshidfar F; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
McNamara MG; Department of Medical Oncology, The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.
Knox JJ; Department of Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada.
Kopciuk K; Department of Mathematics and Biostatistics, University of Calgary, Calgary, Canada.
Vogel HJ; Department of Biological Sciences, University of Calgary, Calgary, Canada.
Bathe OF; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.; Department of Surgery, University of Calgary, Calgary, Canada.; Department of Oncology, University of Calgary, Calgary, Canada.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2019 Apr 02; Vol. 14 (4), pp. e0213942. Date of Electronic Publication: 2019 Apr 02 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Biomarkers, Tumor/*blood
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Metabolome/*drug effects
Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Axitinib/pharmacology ; Axitinib/therapeutic use ; Biomarkers, Tumor/metabolism ; Carcinoma, Hepatocellular/blood ; Carcinoma, Hepatocellular/metabolism ; Cell Line, Tumor ; Clinical Trials, Phase II as Topic ; Disease Progression ; Drug Monitoring/methods ; Drug Resistance, Neoplasm/drug effects ; Humans ; Liver Neoplasms/blood ; Liver Neoplasms/metabolism ; Metabolomics/methods ; Treatment Outcome
Czasopismo naukowe
Tytuł:
T-bet memory B cells: Generation, function, and fate.
Autorzy:
Knox JJ; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Myles A; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Cancro MP; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Pokaż więcej
Źródło:
Immunological reviews [Immunol Rev] 2019 Mar; Vol. 288 (1), pp. 149-160.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
MeSH Terms:
Autoantibodies/*metabolism
B-Lymphocyte Subsets/*immunology
B-Lymphocytes/*immunology
T-Box Domain Proteins/*metabolism
Animals ; Autoimmunity ; Cell Differentiation ; Cytokines/metabolism ; Humans ; Immunologic Memory ; Lymphocyte Activation ; Mice ; Signal Transduction ; T-Box Domain Proteins/genetics ; Toll-Like Receptors/metabolism
Czasopismo naukowe
Tytuł:
Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study.
Autorzy:
Doherty MK; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
Leung Y; Department of Psychosocial Oncology, Princess Margaret Cancer Centre, British Colombia, Canada.
Su J; Department of Biostatistics, Princess Margaret Cancer Centre, British Colombia, Canada.
Naik H; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Patel D; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Eng L; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Kong QQ; Department of Biostatistics, Princess Margaret Cancer Centre, British Colombia, Canada.
Mohsin F; Department of Biostatistics, Princess Margaret Cancer Centre, British Colombia, Canada.
Brown MC; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Espin-Garcia O; Department of Biostatistics, Princess Margaret Cancer Centre, British Colombia, Canada.
Vennettilli A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Renouf DJ; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; BC Cancer Agency, University of British Columbia, Vancouver, British Colombia, Canada.
Faluyi OO; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Department of Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, UK.
Knox JJ; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
MacKay H; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
Wong R; Radiation Medicine Program, University of Toronto, Toronto, Ontario.
Howell D; Department of Psychosocial Oncology, Princess Margaret Cancer Centre, British Colombia, Canada.
Mittmann N; Cancer Care Ontario, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario.
Darling GE; Department of Surgery, Princess Margaret Cancer Centre, Chicago, Illinois, USA.
Cella D; Department of Medical Social Sciences, Northwestern University, Chicago, Illinois, USA.
Xu W; Department of Biostatistics, Princess Margaret Cancer Centre, British Colombia, Canada.
Liu G; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Pokaż więcej
Źródło:
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus [Dis Esophagus] 2018 Dec 01; Vol. 31 (12).
Typ publikacji:
Journal Article
MeSH Terms:
Health Status*
Quality of Life*
Severity of Illness Index*
Esophageal Neoplasms/*diagnosis
Adult ; Aged ; Aged, 80 and over ; Cross-Sectional Studies ; Female ; Humans ; Linear Models ; Male ; Middle Aged ; Multivariate Analysis ; Statistics, Nonparametric ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł:
Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database.
Autorzy:
Samawi HH; British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Sim HW; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Chan KK; Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
Alghamdi MA; King Saud University, Riyadh, Saudi Arabia.
Lee-Ying RM; Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Knox JJ; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Gill P; British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Romagnino A; Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
Batuyong E; Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Ko YJ; Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
Davies JM; British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Lim HJ; British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Cheung WY; Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Tam VC; Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Pokaż więcej
Corporate Authors:
CHORD Consortium
Źródło:
Cancer medicine [Cancer Med] 2018 Jul; Vol. 7 (7), pp. 2816-2825. Date of Electronic Publication: 2018 May 15.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Characterizing the outcomes of metastatic papillary renal cell carcinoma.
Autorzy:
Connor Wells J; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.; Queen's University, Kingston, Ontario, Canada.
Donskov F; Aarhus University Hospital, Aarhus, Denmark.
Fraccon AP; Casa di Cura Pederzoli, Peschiera Del Garda, Italy.
Pasini F; Medical Oncology Department, Ospedale Santa Maria della Misericordia, Rovigo, Italy.
Bjarnason GA; Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
Beuselinck B; University Hospitals Leuven, Leuven, Belgium.
Knox JJ; Princess Margaret Hospital, Toronto, Ontario, Canada.
Rha SY; Yonsei University College of Medicine, Seoul, South Korea.
Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Bowman IA; University of Texas Southwestern Medical Center, Dallas, Texas.
Lee JL; Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Pal SK; City of Hope Comprehensive Cancer Center, Duarte, California.
Srinivas S; Stanford Cancer Center, Stanford, California.
Scott Ernst D; London Health Sciences Center, London, Ontario, Canada.
Vaishampayan UN; Karmanos Cancer Institute, Detroit, Michigan.
Wood LA; Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.
Simpson R; Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.
De Velasco G; Dana Farber Cancer Institute, Boston, Massachusetts.
Choueiri TK; Dana Farber Cancer Institute, Boston, Massachusetts.
Heng DYC; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2017 May; Vol. 6 (5), pp. 902-909. Date of Electronic Publication: 2017 Apr 16.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Molecular Targeted Therapy/*methods
Carcinoma, Renal Cell/pathology ; Clinical Trials as Topic ; Disease-Free Survival ; Female ; Humans ; Kidney Neoplasms/pathology ; Male ; Neoplasm Metastasis ; Prognosis ; Standard of Care ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
Autorzy:
McNamara MG; Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK. .
Bridgewater J; UCL Cancer Institute, London, WCIE 6BT, UK.
Lopes A; Cancer Research UK & UCL Cancer Trials Centre, London, WCIE 6BT, UK.
Wasan H; Imperial Healthcare, London, WI2 ONN, UK.
Malka D; Institute Gustave Roussy, 94805, Villejuif, France.
Jensen LH; Vejle Hospital, 7100, Vejle, Denmark.
Okusaka T; National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Knox JJ; Princess Margaret Cancer Centre, Toronto, M5G 2M9, Canada.
Wagner D; Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne, Switzerland.
Cunningham D; Royal Marsden Hospital, London, UK.
Shannon J; University of Sydney, Sydney, NSW, 2006, Australia.
Goldstein D; Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.
Moehler M; Universitätsmedizin Mainz, 55122, Mainz, Germany.
Bekaii-Saab T; Mayo Clinic, Phoenix, AZ, 85054, USA.
Valle JW; Division of Molecular & Clinical Cancer Sciences, Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2017 Apr 12; Vol. 17 (1), pp. 262. Date of Electronic Publication: 2017 Apr 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Biliary Tract Neoplasms/*drug therapy
Biliary Tract Neoplasms/*pathology
Carboplatin/*administration & dosage
Cisplatin/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carboplatin/therapeutic use ; Cisplatin/therapeutic use ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Survival Analysis ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł:
Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival.
Autorzy:
Faluyi OO; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
Eng L; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
Qiu X; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Che J; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Zhang Q; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Cheng D; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
Ying N; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.; Institute of Biomedical Engineering, Hangzhou Dianzi University, Zhejiang, China.
Tse A; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
Kuang Q; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
Dodbiba L; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
Renouf DJ; British Columbia Cancer Agency, Department of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada.
Marsh S; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
Savas S; Discipline of Genetics, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Mackay HJ; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Knox JJ; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
Darling GE; Division of Thoracic Surgery, Department of Surgery, Toronto General Hospital, Toronto, Ontario, Canada.
Wong RK; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Xu W; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Azad AK; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
Liu G; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.; Division of Applied Molecular Oncology, Ontario Cancer Institute-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2017 Feb; Vol. 6 (2), pp. 361-373. Date of Electronic Publication: 2017 Jan 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Regulatory Networks*
Polymorphism, Single Nucleotide*
Adenocarcinoma/*genetics
Esophageal Neoplasms/*genetics
MicroRNAs/*genetics
Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Prognosis ; Proportional Hazards Models ; Survival Analysis
SCR Disease Name:
Adenocarcinoma Of Esophagus
Czasopismo naukowe
Tytuł:
Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.
Autorzy:
Horgan AM; Department of Medical Oncology, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Darling G; Department of Surgical Oncology, Division of Thoracic Surgery, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Wong R; Department of Radiation Oncology, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Guindi M; Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California, USA.
Liu G; Department of Medical Oncology, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Jonker DJ; Department of Medical Oncology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Lister J; Department of Surgical Oncology, Division of Thoracic Surgery, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Xu W; Department of Biostatistics, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
MacKay HM; Department of Medical Oncology, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Dinniwell R; Department of Radiation Oncology, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Kim J; Department of Radiation Oncology, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Pierre A; Department of Surgical Oncology, Division of Thoracic Surgery, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Shargall Y; Division of Thoracic Surgery, McMaster University, Hamilton, Ontario, Canada.
Asmis TR; Department of Medical Oncology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Agboola O; Department of Thoracic Surgery, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Seely AJ; Department of Pathology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Ringash J; Department of Radiation Oncology, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Wells J; Department of Radiation Oncology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Marginean EC; Department of Pathology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Haider M; Department of Medical Oncology, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Knox JJ; Department of Medical Oncology, Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Ontario, Canada.
Pokaż więcej
Źródło:
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus [Dis Esophagus] 2016 Nov; Vol. 29 (8), pp. 1152-1158. Date of Electronic Publication: 2015 Dec 10.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Antineoplastic Agents/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Esophageal Neoplasms/*therapy
Indoles/*administration & dosage
Pyrroles/*administration & dosage
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Chemoradiotherapy ; Chemotherapy, Adjuvant/mortality ; Cisplatin/administration & dosage ; Esophageal Neoplasms/mortality ; Esophageal Neoplasms/pathology ; Esophagectomy ; Esophagogastric Junction/pathology ; Feasibility Studies ; Female ; Humans ; Indoles/adverse effects ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local/mortality ; Neoplasm Staging ; Postoperative Period ; Pyrroles/adverse effects ; Sunitinib ; Survival Rate ; Withholding Treatment/statistics & numerical data
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies